<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185182</url>
  </required_header>
  <id_info>
    <org_study_id>RCCSCAN</org_study_id>
    <secondary_id>2016-005182-31</secondary_id>
    <nct_id>NCT03185182</nct_id>
  </id_info>
  <brief_title>Diagnostic Imaging for Clear Cell Renal Cell Carcinoma</brief_title>
  <acronym>RCCSCAN</acronym>
  <official_title>&quot;An Exploratory Study Regarding the Use of the Biomarker Dopamine Transporter (DAT) for Image Diagnosis of Clear Cell Renal Cell Carcinoma&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to study whether imaging detection of the biomarker DAT can be used to
      detect kidney tumors identified by computer tomography (CT), which are pathologically
      assesses as being of the clear cell subtype.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ccRCC detection</measure>
    <time_frame>The results from the last enrolled patient is expected to be obtained 14 months after initiation</time_frame>
    <description>The primary endpoint is to investigate if tumors detected with CT display Ioflupane positivity in patients with verified clear cell renal cell carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>non-ccRCC negative for ioflupane I123</measure>
    <time_frame>The results from the last enrolled patient is expected to be obtained 14 months after initiation</time_frame>
    <description>Ioflupane I123 displays no positive signal in lesions identifies by CT in patients with tumors classified as non-clear cell renal cell carcinoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>185 megabecquerel (MBq) of Ioflupane I-123 will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ioflupane I123</intervention_name>
    <description>185 MBq ioflupane I133 will be administered at one single occasion to the study subjects</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspected kidney cancer diagnosis

          -  suspected spread of the cancer

          -  patient is scheduled for surgery alternatively biopsy of kidney tumor

          -  patient is 18 years or older

          -  the patient has given their consent to participate in the study

          -  female patients of reproductive age displays negative pregnancy test

        Exclusion Criteria:

          -  known or suspected allergy to Ioflupane or sodium acetate or acetic acid or ethanol

          -  patient suffers from moderate to severe renal impairment and exhibits glomerular
             filtration rate (GFR) &lt;40

          -  patient is medicated for Parkinson's disease

          -  patient is medicated with any of the following medications: amphetamine, benzatropine,
             buproprion, cocaine, mazindol, methylphenidate, phentermine, sertraline, levodopa,
             dexamphetamine, lisdexamphetamine, modafinil, moclobemid, venlafaxine

          -  patient is pregnant

          -  breastfeeding

          -  patient suffers from mental inability unwillingness or language difficulties resulting
             in difficulty in understanding the meaning of taking part in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Elfving, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Skane</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Håkan Axelson, PhD</last_name>
    <phone>+46 462226434</phone>
    <email>hakan.axelson@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skåne University hospital SUS</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnosis</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

